Best timing for estrogen-receptor imaging scans
Part of Cancer, Skin clinical trials.
This study helps doctors figure out the best time to take imaging pictures after an estrogen-receptor tracer injection. You'll get a PET/CT scan (a detailed imaging test) and help researchers understand how to get the clearest pictures for better cancer diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already scheduled for or referred for a PET/CT scan using an estrogen-receptor tracer (18F-Fluoroestradiol)
- You are able to lie flat on your back for up to one hour without major discomfort
- You can follow instructions during the imaging procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This trial compares two types of PET scans to see which one better detects ER-positive breast cancer. The results could help doctors choose the best scan for tracking your cancer.
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.